Cutaneous Squamous Cell Carcinoma (cSCC) - Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026

Cutaneous Squamous Cell Carcinoma Emerging Therapy and TPP Insights

Thelansis's "Cutaneous Squamous Cell Carcinoma (cSCC) Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026" provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Cutaneous Squamous Cell Carcinoma (cSCC) Overview

Cutaneous squamous cell carcinoma (cSCC) is a common skin cancer that is usually curable with surgery when caught early, but a meaningful subset of cases become locally advanced, recurrent, or metastatic, at which point outcomes historically worsened sharply and treatment options were limited. That calculus changed with the arrival of PD-1 checkpoint immunotherapy, which delivered durable disease control for patients whose cancer could no longer be managed surgically and quickly became the established standard for advanced disease. More recently, the same mechanism has moved earlier in the treatment journey, with regulators now supporting its use after surgery and radiation in patients considered high risk for recurrence, and clinical investigation extending further into shrinking tumors before surgery altogether. This progression signals a broader shift in cSCC: immunotherapy is no longer a last resort for advanced disease but a tool woven throughout the treatment continuum, aimed at preventing recurrence rather than only responding once disease has spread. For stakeholders, cSCC shows how one validated mechanism can expand across stages to reshape a category's standard of care.

Key Highlights

• In Germany, incident cSCC cases are projected to increase from 38,675 in 2025 to 44,883 by 2035, reflecting a growing disease burden driven by aging populations and cumulative UV exposure.
• cSCC is the second most common non-melanoma skin cancer, with a subset of patients progressing to locally advanced or metastatic disease.
• Rising incidence is associated with increased life expectancy, immunosuppression, and improved detection rates.
• Growing adoption of immunotherapy is improving outcomes in advanced cSCC patients.

Market Overview

• The Germany cSCC market is projected to grow from $189M in 2025 to $357M by 2035.
• Market growth is driven by:
• Increasing incidence and diagnosis rates
• Adoption of immune checkpoint inhibitors for advanced disease
• Future growth will depend on earlier diagnosis and expansion of immuno-oncology therapies.

Insights driven by surveys with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs
• Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Replimune, Inc.
• Incyte Corporation
• Regeneron Pharmaceuticals
• Merck Sharp & Dohme LLC
• Philogen S.p.A.
• EvolveImmune United, Inc.
• Rakuten Medical, Inc.
• Hummingbird Bioscience
• Ankyra Therapeutics, Inc.
• Bicara Therapeutics
• KaliVir Immunotherapeutics
• Immunitas Therapeutics
• Memgen, Inc.
• Boundless Bio, Inc.
• Medicenna Therapeutics, Inc.